Table 1.
Characteristics of SHFS participants stratified by field center
| Arizona | Dakota | Oklahoma | Combined | |
|---|---|---|---|---|
| Echo (ECG) sample size | 1204 (1187) | 1173 (1186) | 1193 (1148) | 3567 (3521) |
| Female, n (%) | 752 (62) | 695 (59) | 698 (59) | 2145 (60) |
| Age (years), mean (±SD) | 37.09 (15.9) | 38.91 (17.10) | 43.58 (17.29) | 39.85 (16.99) |
| Echo HR (b.p.m.), mean (±SD) | 66.49 (10.47) | 66.65 (11.03) | 68.06 (10.71) | 67.06 (10.76) |
| ECG HR (b.p.m.), mean (±SD) | 65.15 (10.51) | 64.04 (10.47) | 65.04 (10.25) | 64.80 (10.53) |
| Height (m), mean (±SD) | 1.65 (8.7)* | 1.69 (8.75) | 1.67 (9.14) | 1.67 (9.07) |
| Body mass index, mean (±SD) | 35.12 (8.17) | 30.14 (6.82) | 31.18 (6.90) | 32.14 (7.62) |
| Hypertensive medication, current n (%) | 268 (22) | 180 (15) | 274 (23) | 722 (20) |
| Lean body mass (kg) (±SD) | 54.93 (12.37) | 56.04 (12.38) | 54.77 (12.50) | 55.24 (12.43) |
| Fat mass (kg) (±SD) | 41.43 (9.7) | 34.17 (10.02) | 36.33 (9.41) | 37.33 (10.19)** |
| HOMAIR, mean (±SD) | 4.57 (4.29) | 4.12 (5.18) | 3.16 (3.08) | 3.92 (4.32) |
| Fasting insulin (µU/ml), mean (±SD) | 19.69 (14.26) | 17.01 (14.89) | 15.52 (13.49) | 17.42 (14.32) |
| Fasting glucose(mg/dl), mean (±SD) | 121.68 (55.48) | 104.20 (33.66) | 106.59 (37.78) | 110.83 (44.05) |
| HBA1C (%) (±SD) | 7.26 (2.30) | 6.09 (1.61) | 6.62 (1.89) | 6.71 (2.05) |
| Diastolic blood pressure (mmHg), mean (±SD) | 76.48 (11.33) | 75.13 (10.48) | 76.83 (11.52) | 76.15 (11.14) |
| Systolic blood pressure (mmHg), mean (±SD) | 120.75 (16.50) | 119.71 (15.32) | 126.52 (16.86) | 122.33 (16.51) |
| Mean arterial blood pressure (mmHg), mean (±SD) | 91.29 (11.53) | 90.01 (10.71) | 93.46 (11.66) | 91.60 (11.40) |
| Pulse pressure mean (mmHg) (±SD) | 44.05 (13.87) | 44.40 (12.51) | 49.53 (14.43) | 45.99 (13.85) |
| Alcohol, current n (%) | 709 (59) | 777 (66) | 566 (47) | 2053 (58) |
| Smokers, current n (%) | 307 (25) | 500 (43) | 397 (33) | 1204 (34) |
NS, not statistically significant; Echo, echocardiograph; ECG, electrocardiogram; HOMAIR, homeostasis model assessment of insulin resistance; HBA1C, glycosylated hemoglobin.
*Statistically significant with Echo HR levels at P-value <0.05.
**Statistically significant with Echo HR levels at P-value <0.01.